Second Department of Critical Care, Attikon General University Hospital, Medical School, National and Kapodistrian University of Athens, 1 Rimini St., Haidari, 12462 Athens, Greece.
Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Mikras Asias 75, Goudi, 11527 Athens, Greece.
Biomolecules. 2022 Feb 12;12(2):301. doi: 10.3390/biom12020301.
Chemerin, a novel adipokine, is a potent chemoattractant molecule with antimicrobial properties, implicated in immune responses. Our aim was to investigate circulating chemerin and its kinetics, early in sepsis in critically ill patients and its association with severity and prognosis. Serum chemerin was determined in a cohort of 102 critically ill patients with sepsis during the first 48 h from sepsis onset and one week later, and in 102 age- and gender-matched healthy controls. Patients were followed for 28 days and their outcomes were recorded. Circulating chemerin was significantly higher in septic patients at onset compared to controls (342.3 ± 108.1 vs. 200.8 ± 40.1 μg/L, < 0.001). Chemerin decreased significantly from sepsis onset to one week later (342.3 ± 108.1 vs. 308.2 ± 108.5 μg/L, < 0.001), but remained higher than in controls. Chemerin was higher in patients presenting with septic shock than those with sepsis (sepsis onset: 403.2 ± 89.9 vs. 299.7 ± 99.5 μg/L, < 0.001; one week after: 374.9 ± 95.3 vs. 261.6 ± 91.9 μg/L, < 0.001), and in nonsurvivors than survivors (sepsis onset: 427.2 ± 96.7 vs. 306.9 ± 92.1 μg/L, < 0.001; one week after: 414.1 ± 94.5 vs. 264.2 ± 79.9 μg/L, < 0.001). Moreover, patients with septic shock and nonsurvivors, presented a significantly lower absolute and relative decrease in chemerin one week after sepsis onset compared to baseline ( < 0.001). Based on ROC curve analyses, the diagnostic performance of chemerin (AUC 0.78, 95% CI 0.69-0.87) was similar to C-reactive protein (CRP) (AUC 0.78, 95% CI 0.68-0.87) in discriminating sepsis severity. However, increased chemerin at sepsis onset and one week later was an independent predictor of 28-day mortality (sepsis onset: HR 3.58, 95% CI 1.48-8.65, = 0.005; one week after: HR 10.01, 95% CI 4.32-23.20, < 0.001). Finally, serum chemerin exhibited significant correlations with the severity scores, white blood cells, lactate, CRP and procalcitonin, as well as with biomarkers of glucose homeostasis, but not with cytokines and soluble urokinase-type plasminogen activator receptor (suPAR). Circulating chemerin is increased early in sepsis and its kinetics may have diagnostic and prognostic value in critically ill patients. Further studies are needed to shed light on the role of chemerin in sepsis.
Chemerin,一种新型脂肪因子,是一种具有抗菌特性的强效趋化因子分子,与免疫反应有关。我们的目的是研究脓毒症患者发病初期循环 chemerin 的变化及其动力学特征,及其与严重程度和预后的关系。在脓毒症发病的头 48 小时内和一周后,我们检测了 102 例重症脓毒症患者和 102 例年龄和性别匹配的健康对照者的血清 chemerin。对患者进行了 28 天的随访并记录了他们的结局。与对照组相比,发病时脓毒症患者的循环 chemerin 明显升高(342.3 ± 108.1 比 200.8 ± 40.1 μg/L, <0.001)。从发病到一周后,chemerin 明显下降(342.3 ± 108.1 比 308.2 ± 108.5 μg/L, <0.001),但仍高于对照组。与脓毒症患者相比,脓毒性休克患者的 chemerin 更高(发病时:403.2 ± 89.9 比 299.7 ± 99.5 μg/L, <0.001;一周后:374.9 ± 95.3 比 261.6 ± 91.9 μg/L, <0.001),且非幸存者比幸存者更高(发病时:427.2 ± 96.7 比 306.9 ± 92.1 μg/L, <0.001;一周后:414.1 ± 94.5 比 264.2 ± 79.9 μg/L, <0.001)。此外,与存活者相比,脓毒性休克和非存活者在发病后一周时,chemerin 的绝对和相对下降幅度明显较低( <0.001)。基于 ROC 曲线分析,chemerin(AUC 0.78,95% CI 0.69-0.87)的诊断性能与 C 反应蛋白(CRP)(AUC 0.78,95% CI 0.68-0.87)相似,可区分脓毒症严重程度。然而,发病时和一周后 chemerin 的升高是 28 天死亡率的独立预测因子(发病时:HR 3.58,95% CI 1.48-8.65, =0.005;一周后:HR 10.01,95% CI 4.32-23.20, <0.001)。最后,血清 chemerin 与严重程度评分、白细胞、乳酸、CRP 和降钙素原显著相关,与葡萄糖稳态的生物标志物显著相关,但与细胞因子和可溶性尿激酶型纤溶酶原激活物受体(suPAR)不相关。循环 chemerin 在脓毒症早期升高,其动力学特征对重症患者具有诊断和预后价值。还需要进一步的研究来阐明 chemerin 在脓毒症中的作用。